{"id":"methylnaltrexone-mntx","safety":{"commonSideEffects":[{"rate":"29","effect":"Abdominal pain"},{"rate":"26","effect":"Diarrhea"},{"rate":"22","effect":"Nausea"},{"rate":"13","effect":"Flatulence"},{"rate":"7","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1186579","moleculeType":"Small molecule","molecularWeight":"356.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylnaltrexone is a quaternary amine derivative of naltrexone that selectively antagonizes mu-opioid receptors located in the peripheral nervous system of the gastrointestinal tract. Because it is highly polar and does not cross the blood-brain barrier, it blocks the constipating effects of opioids on the gut while preserving the analgesic and other central nervous system effects of opioid therapy. This mechanism allows patients on chronic opioid therapy to maintain pain relief while restoring normal bowel function.","oneSentence":"Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:44.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid-induced constipation in patients with chronic non-cancer pain"},{"name":"Opioid-induced constipation in patients with advanced illness receiving palliative care"}]},"trialDetails":[{"nctId":"NCT04930237","phase":"","title":"RELISTOR's Effects on Opioid-Induced Constipation","status":"WITHDRAWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"OIC","enrollment":""},{"nctId":"NCT04787848","phase":"NA","title":"Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics","status":"RECRUITING","sponsor":"Florida International University","startDate":"2021-11-15","conditions":"Chronic Widespread Pain","enrollment":200},{"nctId":"NCT06162377","phase":"PHASE4","title":"Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT03523520","phase":"PHASE4","title":"Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2020-12-23","conditions":"Constipation Drug Induced","enrollment":15},{"nctId":"NCT04743570","phase":"PHASE2, PHASE3","title":"Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis","status":"COMPLETED","sponsor":"Asbjørn Mohr Drewes","startDate":"2021-05-14","conditions":"Acute Pancreatitis","enrollment":105},{"nctId":"NCT01367561","phase":"PHASE1","title":"Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-10","conditions":"Healthy Males","enrollment":15},{"nctId":"NCT02977286","phase":"PHASE4","title":"Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2017-01-01","conditions":"Constipation","enrollment":12},{"nctId":"NCT01015222","phase":"PHASE1","title":"Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Advanced Cancer","enrollment":122},{"nctId":"NCT03852524","phase":"PHASE2","title":"Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-02-21","conditions":"Postoperative Ileus","enrollment":82},{"nctId":"NCT04151719","phase":"PHASE3","title":"An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-02-03","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT04083651","phase":"PHASE2, PHASE3","title":"A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-01-06","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT00547586","phase":"PHASE2","title":"Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10","conditions":"Constipation","enrollment":122},{"nctId":"NCT00936884","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-07","conditions":"Constipation","enrollment":50},{"nctId":"NCT00858754","phase":"PHASE4","title":"Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects","status":"WITHDRAWN","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-03","conditions":"Opioid-Induced Constipation","enrollment":""},{"nctId":"NCT01363323","phase":"PHASE1","title":"Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-11","conditions":"Healthy Volunteers","enrollment":546},{"nctId":"NCT01366326","phase":"PHASE1","title":"Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-07","conditions":"Healthy Adult Subjects","enrollment":20},{"nctId":"NCT01367587","phase":"PHASE2","title":"Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT01366365","phase":"PHASE1","title":"Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-10","conditions":"Healthy Adults","enrollment":28},{"nctId":"NCT01366352","phase":"PHASE1","title":"Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-02","conditions":"Normal Volunteers","enrollment":24},{"nctId":"NCT01367535","phase":"PHASE1","title":"Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-03","conditions":"Healthy Adults","enrollment":54},{"nctId":"NCT01367600","phase":"PHASE3","title":"Open-Label Treatment Extension of Protocol MNTX 301","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-02","conditions":"Terminal Illness","enrollment":27},{"nctId":"NCT01367548","phase":"PHASE2","title":"Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-07","conditions":"Postoperative Ileus","enrollment":65},{"nctId":"NCT01367496","phase":"PHASE1","title":"Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-06","conditions":"Healthy Subjects","enrollment":6},{"nctId":"NCT01367509","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Renal Impairment","enrollment":32},{"nctId":"NCT01366339","phase":"PHASE1","title":"Tolerance and Pharmacokinetics Study of MNTX Tablets","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-10","conditions":"Normal Healthy Volunteers","enrollment":37},{"nctId":"NCT01367483","phase":"PHASE1","title":"Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-06","conditions":"Healthy Male Volunteers","enrollment":6},{"nctId":"NCT01367574","phase":"PHASE2","title":"Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-04","conditions":"Bowel Dysfunction","enrollment":39},{"nctId":"NCT01367522","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Liver Dysfunction","enrollment":24},{"nctId":"NCT01366378","phase":"PHASE1","title":"Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-01","conditions":"Healthy Adult Subjects","enrollment":18},{"nctId":"NCT01367613","phase":"PHASE3","title":"Open-Label Treatment Extension of Protocol MNTX 302","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Terminal Illness","enrollment":89},{"nctId":"NCT00529087","phase":"PHASE3","title":"Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-08","conditions":"Constipation","enrollment":460},{"nctId":"NCT00402038","phase":"PHASE3","title":"Study of Methylnaltrexone (MNTX) for the Relief of Constipation","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-02","conditions":"Advance Illness Patients With OIC","enrollment":134},{"nctId":"NCT00401362","phase":"PHASE3","title":"A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-02","conditions":"Advanced Illness Patients With Opioid Induced Constipation","enrollment":154},{"nctId":"NCT00387309","phase":"PHASE3","title":"Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-12","conditions":"Post Operative Bowel Dysfunction","enrollment":495},{"nctId":"NCT00804141","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-12-03","conditions":"Constipation","enrollment":1040},{"nctId":"NCT01186770","phase":"PHASE3","title":"A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-09-01","conditions":"Opioid-Induced Constipation","enrollment":804},{"nctId":"NCT00528970","phase":"PHASE3","title":"A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10-17","conditions":"Ileus","enrollment":374},{"nctId":"NCT00640146","phase":"PHASE2","title":"Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10-19","conditions":"Opioid-induced Constipation","enrollment":37},{"nctId":"NCT01368562","phase":"NA","title":"Compassionate Use Study of Methylnaltrexone","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-01-24","conditions":"Opioid-induced Constipation","enrollment":26},{"nctId":"NCT00401375","phase":"PHASE3","title":"Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-10-31","conditions":"Post-Operative Ileus (POI)","enrollment":524},{"nctId":"NCT01955213","phase":"","title":"Methylnaltrexone for Opioid Induced Constipation","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2012-07","conditions":"Constipation","enrollment":7},{"nctId":"NCT02942550","phase":"PHASE4","title":"Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2016-11","conditions":"STEMI, Morphine, Ticagrelor","enrollment":82},{"nctId":"NCT00672477","phase":"PHASE4","title":"Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Opioid-Induced Constipation","enrollment":237},{"nctId":"NCT00672139","phase":"PHASE4","title":"Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-07","conditions":"Opioid-Induced Constipation","enrollment":156},{"nctId":"NCT03283020","phase":"PHASE4","title":"Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume","status":"UNKNOWN","sponsor":"Region Örebro County","startDate":"2017-11-11","conditions":"Pharyngeal Dysfunction, Pharyngeal Swallowing","enrollment":20},{"nctId":"NCT02403830","phase":"PHASE4","title":"Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine","status":"COMPLETED","sponsor":"University of Florida","startDate":"2015-08","conditions":"Coronary Artery Disease","enrollment":30},{"nctId":"NCT03014843","phase":"NA","title":"The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-10","conditions":"Endogenous and Esophageal Sensitivity","enrollment":12},{"nctId":"NCT01889290","phase":"PHASE1","title":"Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-02","conditions":"Opioid Use, Unspecified With Other Opioid-induced Disorder","enrollment":9},{"nctId":"NCT01596777","phase":"PHASE1","title":"Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2010-01","conditions":"Intestinal Obstruction","enrollment":15},{"nctId":"NCT01004393","phase":"PHASE2","title":"Methylnaltrexone for Opioid-induced Constipation in Cancer Patients","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2009-10","conditions":"Neoplasms, Constipation, Opioid-Related Disorders","enrollment":12},{"nctId":"NCT00949377","phase":"PHASE4","title":"Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?","status":"WITHDRAWN","sponsor":"Beth Israel Medical Center","startDate":"2009-09","conditions":"Colonic Inertia","enrollment":""},{"nctId":"NCT02574819","phase":"PHASE2, PHASE3","title":"Study of Methylnaltrexone in Opioid-Induced Constipation Patients","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2015-04","conditions":"Opioid-induced Constipation","enrollment":198},{"nctId":"NCT01773096","phase":"PHASE4","title":"Methylnaltrexone Use for Opioid-induced Postoperative Constipation","status":"COMPLETED","sponsor":"Shriners Hospitals for Children","startDate":"2013-05","conditions":"Constipation","enrollment":60},{"nctId":"NCT01360372","phase":"PHASE3","title":"Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates","status":"WITHDRAWN","sponsor":"Drexel University","startDate":"2010-10","conditions":"Tube Feeding","enrollment":""},{"nctId":"NCT01055704","phase":"PHASE4","title":"Effect of Methylnaltrexone on GI Transit in Healthy Volunteers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-11","conditions":"Gastric Motility Disorder","enrollment":48},{"nctId":"NCT01596764","phase":"PHASE1","title":"Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2011-05","conditions":"Intestinal Obstruction","enrollment":16},{"nctId":"NCT01012960","phase":"PHASE4","title":"Opioids and Esophageal Function","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2009-11","conditions":"Pharyngeal Dysfunction, Esophageal Dysfunction","enrollment":13},{"nctId":"NCT01117376","phase":"PHASE2","title":"Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients","status":"TERMINATED","sponsor":"Shiraz University of Medical Sciences","startDate":"2010-05","conditions":"Gastroparesis","enrollment":42},{"nctId":"NCT01050595","phase":"PHASE3","title":"Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit","status":"UNKNOWN","sponsor":"St. John Health System, Michigan","startDate":"2009-12","conditions":"Opioid-induced Constipation","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Relistor®","Relistor"],"phase":"marketed","status":"active","brandName":"Methylnaltrexone (MNTX)","genericName":"Methylnaltrexone (MNTX)","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation. Used for Opioid-induced constipation in patients with chronic non-cancer pain, Opioid-induced constipation in patients with advanced illness receiving palliative care.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}